1. Home
  2. IPHA vs FENC Comparison

IPHA vs FENC Comparison

Compare IPHA & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IPHA
  • FENC
  • Stock Information
  • Founded
  • IPHA 1999
  • FENC 1996
  • Country
  • IPHA France
  • FENC United States
  • Employees
  • IPHA N/A
  • FENC N/A
  • Industry
  • IPHA Biotechnology: Pharmaceutical Preparations
  • FENC Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • IPHA Health Care
  • FENC Health Care
  • Exchange
  • IPHA Nasdaq
  • FENC Nasdaq
  • Market Cap
  • IPHA 178.0M
  • FENC 172.8M
  • IPO Year
  • IPHA 2019
  • FENC 2001
  • Fundamental
  • Price
  • IPHA $2.07
  • FENC $5.92
  • Analyst Decision
  • IPHA Strong Buy
  • FENC Strong Buy
  • Analyst Count
  • IPHA 1
  • FENC 2
  • Target Price
  • IPHA $11.50
  • FENC $14.00
  • AVG Volume (30 Days)
  • IPHA 1.5M
  • FENC 165.5K
  • Earning Date
  • IPHA 09-12-2024
  • FENC 11-07-2024
  • Dividend Yield
  • IPHA N/A
  • FENC N/A
  • EPS Growth
  • IPHA N/A
  • FENC N/A
  • EPS
  • IPHA N/A
  • FENC N/A
  • Revenue
  • IPHA $36,202,722.00
  • FENC $49,348,000.00
  • Revenue This Year
  • IPHA N/A
  • FENC $97.94
  • Revenue Next Year
  • IPHA $102.87
  • FENC $11.50
  • P/E Ratio
  • IPHA N/A
  • FENC N/A
  • Revenue Growth
  • IPHA N/A
  • FENC 278.09
  • 52 Week Low
  • IPHA $1.29
  • FENC $3.96
  • 52 Week High
  • IPHA $3.51
  • FENC $11.92
  • Technical
  • Relative Strength Index (RSI)
  • IPHA 53.12
  • FENC 54.12
  • Support Level
  • IPHA $1.47
  • FENC $5.51
  • Resistance Level
  • IPHA $2.36
  • FENC $6.17
  • Average True Range (ATR)
  • IPHA 0.32
  • FENC 0.37
  • MACD
  • IPHA 0.06
  • FENC -0.08
  • Stochastic Oscillator
  • IPHA 29.99
  • FENC 32.61

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

About FENC Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.

Share on Social Networks: